Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fresenius Kabi Concedes On FDA Pegfilgrastim Chances

German Firm Also Rules Out Humira Interchangeability Designation

Executive Summary

Fresenius Kabi is continuing to suffer from the longstanding effects of the US FDA backlog for onsite inspection reviews amid the coronavirus pandemic. Management discussed Kabi’s latest prospects on its proposed pegfilgrastim biosimilar, as well as adalimumab and tocilizumab.

You may also be interested in...



Kabi: US Pegfilgrastim Crowd Is An Opportunity For Us, Not A Deterrent

In the second part of Generics Bulletin’s exclusive interview with Fresenius Kabi’s senior vice president for biosimilars in the US, Ali Ahmed, he explains why Kabi is relishing the prospect of competing in pegfilgrastim and what the acquisition of mAbxience means for the company’s prospects and vision.

Fresenius Delivers First US Biosimilar Approval

Fresenius Kabi has set out launch plans after receiving its first US biosimilar approval, for its Stimufend pegfilgrastim rival to Neulasta.

Kabi Urges Caution And Patience On Subcutaneous Bortezomib Launch

Fresenius Kabi’s Q1 call spanned its recent launch of a generic version of Takeda’s Velcade subcutaneous injectable to the company’s continued ambitions in biosimilars, with the German firm’s acquisition of a controlling stake in mAbxience scheduled to close by the middle of the year.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151385

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel